Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy

Intrahepatic cholangiocarcinoma (CCA), always diagnosed at an advanced stage in recent years, is of high aggression and poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted agents or immune checkpoint inhibitors approved for advanced intrahepatic CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yuan, Han, Xin, Sun, Zhongquan, Tang, Jinlong, Wu, Yingsheng, Wang, Weilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435785/
https://www.ncbi.nlm.nih.gov/pubmed/34527576
http://dx.doi.org/10.3389/fonc.2021.691380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435785/
https://www.ncbi.nlm.nih.gov/pubmed/34527576
http://dx.doi.org/10.3389/fonc.2021.691380

Ejemplares similares